Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.55 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1205831 | 1.00 | OPRL1 (0.63) | OPRL1CYP1A2CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL8507420 | 1.00 | OPRL1 (0.63) | OPRL1CYP1A2CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL8074159 | 0.98 | CYP1A2 (0.66) | OPRL1CYP1A2CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL13039159 | 0.98 | CYP1A2 (0.66) | OPRL1CYP1A2CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL8074161 | 0.98 | CYP1A2 (0.66) | OPRL1CYP1A2CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL11702651 | 0.85 | OPRL1 (0.49) | OPRL1CYP1A2CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL5139722 | 0.83 | SLC6A4 (0.68) | OPRL1CYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL14035499 | 0.83 | SLC6A4 (0.68) | OPRL1CYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL11651599 | 0.83 | OPRL1 (0.58) | OPRL1CYP1A2CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL7424307 | 0.82 | ADRA2A (0.57) | OPRL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3825318-A1 | OXALAMIDO-SUBSTITUTED TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | Promidis S.r.l. (IT) | 2021-05-26 | — | — | EP | disclosed |
| US-9771362-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-09-26 | — | — | US | disclosed |
| US-9771362-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-09-26 | — | — | US | disclosed |
| US-9771362-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-09-26 | — | — | US | disclosed |
| US-20170066762-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-03-09 | — | — | US | disclosed |
| US-20170066762-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-03-09 | — | — | US | disclosed |
| US-20170066762-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-03-09 | — | — | US | disclosed |
| US-9394301-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-07-19 | — | — | US | disclosed |
| US-9394301-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-07-19 | — | — | US | disclosed |
| US-9394301-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-07-19 | — | — | US | disclosed |
| US-6294557-B1 | ANALGESIC AT CENTRAL NERVOUS SYSTEM IN THE MAMMALIAN SUBJECT. ALSO, THESE COMPOUNDS ARE INFLAMMATORY PAIN CAUSED, FOR EXAMPLE BY BURNS (INDUCED BY A CONTACT WITH HEAT, ACID OR THE OTHER RHEUMATISM OR THE LIKE, IN THE SAID SUBJECT. | PFIZER INC. | 2001-09-25 | — | — | US | disclosed |
| US-6294569-B2 | ANALGESIC AT CENTRAL NERVOUS SYSTEM IN THE MAMMALIAN SUBJECT. ALSO, THESE COMPOUNDS ARE INFLAMMATORY PAIN CAUSED, FOR EXAMPLE BY BURNS (INDUCED BY A CONTACT WITH HEAT, ACID OR THE OTHER RHEUMATISM OR THE LIKE, IN THE SAID SUBJECT. | PFIZER INC. | 2001-09-25 | — | — | US | disclosed |
| US-20010020024-A1 | Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists | ITO FUMITAKA (JP) | 2001-09-06 | — | — | US | disclosed |
| US-20010014683-A1 | Analgesics; side effect reduction | ITO FUMITAKA (JP) | 2001-08-16 | — | — | US | disclosed |
| US-20010011091-A1 | Analgesics | ITO FUMITAKA (JP) | 2001-08-02 | — | — | US | disclosed |
| US-20010009921-A1 | Less tendency to cause drug dependency, analgesic, anesthetic, anti-inflammatory or neuroprotective agent; subtype of opoid receptor | ITO FUMITAKA (JP) | 2001-07-26 | — | — | US | disclosed |
| US-20010008890-A1 | Useful as analgesic, anesthetic, antiinflammatory or neuroprotective agents and in treatment of arthritis, stroke, bowel disease | ITO FUMITAKA (JP) | 2001-07-19 | — | — | US | disclosed |
| US-6201007-B1 | OPIOID KAPPA RECEPTOR AGONISTS; ANALGESICS, ANESTHETICS, NEUROPROTECTIVE AND ANTIINFLAMMATORY AGENTS; STROKES, GASTROINTESTINAL DISORDERS | PFIZER INC. | 2001-03-13 | — | — | US | disclosed |
| US-6110947-A | AN ANALGESIC AGENT FOR TREATING STROKE, ABDOMINAL PAIN; AS ANTIINFLAMMATORY, DIURETIC, ANESTHETIC OR NEUROPROTECTIVE AGENTS | PFIZER INC. (US) | 2000-08-29 | — | — | US | disclosed |
| US-5952369-A | ANALGESIC, TREATMENT FOR STROKE OR ABDOMINAL PAIN ASSOCIATED WITH FUNCTIONAL BOWEL DISEASE | PFIZER INC (US) | 1999-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009921-A1 | Less tendency to cause drug dependency, analgesic, anesthetic, anti-inflammatory or neuroprotective agent; subtype of opoid receptor | OPRL1, OPRD1, OPRK1 | OPRL1 1/4885CYP1A2 282/4885CYP2C19 1154/4885 |
| US-20010011091-A1 | Analgesics | OPRL1, OPRK1, OPRD1 | OPRL1 1/4885CYP1A2 77/4885CYP2C19 543/4885 |
| US-20010020024-A1 | Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists | OPRK1, OPRL1, OPRD1 | OPRL1 2/4885CYP1A2 363/4885CYP2C19 1984/4885 |
| US-20170066762-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | OPRL1 1886/4885CYP1A2 3284/4885CYP2C19 3044/4885 |
| US-20010014683-A1 | Analgesics; side effect reduction | OPRL1, OPRK1, OPRD1 | OPRL1 1/4885CYP1A2 75/4885CYP2C19 691/4885 |
| US-20010008890-A1 | Useful as analgesic, anesthetic, antiinflammatory or neuroprotective agents and in treatment of arthritis, stroke, bowel disease | OPRL1, NAP1L1, OPRK1 | OPRL1 1/4885CYP1A2 433/4885CYP2C19 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.